表紙
市場調査レポート

癌悪液質:パイプライン分析

Cancer Cachexia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 200436
出版日 ページ情報 英文 113 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
癌悪液質:パイプライン分析 Cancer Cachexia - Pipeline Review, H1 2016
出版日: 2016年02月29日 ページ情報: 英文 113 Pages
概要

癌悪液質とは、悪性腫瘍の成長に伴う、段階的な体重低下や食欲不振、宿主体細胞量の持続的侵食などの症候群のことを指します。癌悪液質はしばしば、感染症に罹患した末期前患者と関連付けられますが、悪性腫瘍の兆候が全く見られない初期段階の腫瘍でも生じることがあります。エネルギー消費量の変化(増加も減少も現状維持もあります)に比べての食事量低下が、がんに関連した体重減少につながる根本的・生理的な錯乱につながっています。さらに、宿主の炭水化物・タンパク質・脂肪分の代謝異常のために、十分な栄養サポートにも関わらず、宿主組織の持続的な動態化や満腹感の異常などが生じることがあります。がん由来の食欲不振や感染症状に関する介在物質はまだ発見されていません。他の慢性疾患におけるサイトカイン(悪性腫瘍への防御手段として生成された物)によって生じた似たような代謝異常の事例に基づいて、カケクチン/TNF(腫瘍壊死要因)や、その他の宿主由来のサイトカインが、悪液質のシグナル分子として用いられてきました。栄養サポートが癌悪液質患者の体重維持に有効ですが、痩せ型のボディマスを維持するには効果的とは言えません。

当レポートでは、世界各国での癌悪液質治療用パイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

癌悪液質の概要

治療薬の開発

  • 癌悪液質向けパイプライン製品:概要
  • 癌悪液質向けパイプライン製品:比較分析

各企業で開発中の癌悪液質治療薬

大学/研究機関で研究中の癌悪液質治療薬

癌悪液質のパイプライン製品の概略

  • 最終段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品の一覧(企業別)

研究中の製品の一覧(大学/研究機関別)

癌悪液質治療薬の開発に参加している企業

  • Acacia Pharma Limited
  • Aeterna Zentaris Inc.
  • Aphios Corporation
  • Atara Biotherapeutics, Inc.
  • Eli Lilly and Company
  • Helsinn Healthcare S.A.
  • Incyte Corporation
  • Novartis AG
  • Obexia AG
  • PsiOxus Therapeutics Limited
  • RaQualia Pharma Inc.
  • Viking Therapeutics, Inc.

癌悪液質:治療薬の評価

  • (フマル酸フォルモテロール + 酢酸メゲストロール) anamorelin hydrochloride
  • 癌悪液質用副甲状腺ホルモン関連タンパク質阻害剤
  • 遺伝性疾患・筋骨格障害用カルシニューリン A 活性アプタマー
  • ATA-842
  • AUSRM-057
  • bimagrumab
  • C-1889
  • DLN-101
  • dronabinol
  • espindolol
  • EXT-400
  • Foxo1-nRNA
  • HM-03
  • landogrozumab
  • macimorelin acetate
  • 癌悪液質用 TWEAK受容体拮抗モノクローナル抗体
  • 癌悪液質・悪液質用 TWEAK受容体拮抗モノクローナル抗体
  • NBD ペプチド
  • OBX-1201
  • RQ-00433412
  • ruxolitinib phosphate
  • 癌悪液質・2型糖尿病用 ATGL 阻害小分
  • 癌悪液質用メラノコルチン受容体阻害合成ペプチド
  • 癌悪液質用合成ペプチド
  • tertomotide
  • VK-5211

癌悪液質:パイプライン製品の最新動向

癌悪液質:開発が休止状態の製品

癌悪液質:開発が中止された製品

癌悪液質症関連の製品開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7656IDB

Summary

Global Markets Direct's, 'Cancer Cachexia - Pipeline Review, H1 2016', provides an overview of the Cancer Cachexia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Cachexia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Cachexia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia
  • The report reviews pipeline therapeutics for Cancer Cachexia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cancer Cachexia therapeutics and enlists all their major and minor projects
  • The report assesses Cancer Cachexia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cancer Cachexia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cancer Cachexia Overview
  • Therapeutics Development
    • Pipeline Products for Cancer Cachexia - Overview
    • Pipeline Products for Cancer Cachexia - Comparative Analysis
  • Cancer Cachexia - Therapeutics under Development by Companies
  • Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes
  • Cancer Cachexia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Cancer Cachexia - Products under Development by Companies
  • Cancer Cachexia - Products under Investigation by Universities/Institutes
  • Cancer Cachexia - Companies Involved in Therapeutics Development
    • Acacia Pharma Limited
    • Aeterna Zentaris Inc.
    • Aphios Corporation
    • Atara Biotherapeutics, Inc.
    • Eli Lilly and Company
    • Helsinn Healthcare S.A.
    • Incyte Corporation
    • Novartis AG
    • Obexia AG
    • PsiOxus Therapeutics Limited
    • RaQualia Pharma Inc.
    • Viking Therapeutics, Inc.
  • Cancer Cachexia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (formoterol fumarate + megestrol acetate) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • anamorelin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATA-842 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AUSRM-057 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bimagrumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-1889 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLN-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • espindolol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EXT-400 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Foxo1-nRNA - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HM-03 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • landogrozumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • macimorelin acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia and Cancer Cachexia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NBD Peptide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OBX-1201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00433412 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ruxolitinib phosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides for Cancer Cachexia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tertomotide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VK-5211 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cancer Cachexia - Recent Pipeline Updates
  • Cancer Cachexia - Dormant Projects
  • Cancer Cachexia - Discontinued Products
  • Cancer Cachexia - Product Development Milestones
    • Featured News & Press Releases
      • Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
      • Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102
      • Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130
      • Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130
      • Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference
      • Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study
      • Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia
      • Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102
      • Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics
      • Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cancer Cachexia, H1 2016
  • Number of Products under Development for Cancer Cachexia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Cancer Cachexia - Pipeline by Acacia Pharma Limited, H1 2016
  • Cancer Cachexia - Pipeline by Aeterna Zentaris Inc., H1 2016
  • Cancer Cachexia - Pipeline by Aphios Corporation, H1 2016
  • Cancer Cachexia - Pipeline by Atara Biotherapeutics, Inc., H1 2016
  • Cancer Cachexia - Pipeline by Eli Lilly and Company, H1 2016
  • Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H1 2016
  • Cancer Cachexia - Pipeline by Incyte Corporation, H1 2016
  • Cancer Cachexia - Pipeline by Novartis AG, H1 2016
  • Cancer Cachexia - Pipeline by Obexia AG, H1 2016
  • Cancer Cachexia - Pipeline by PsiOxus Therapeutics Limited, H1 2016
  • Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H1 2016
  • Cancer Cachexia - Pipeline by Viking Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Cancer Cachexia Therapeutics - Recent Pipeline Updates, H1 2016
  • Cancer Cachexia - Dormant Projects, H1 2016
  • Cancer Cachexia - Dormant Projects (Contd..1), H1 2016
  • Cancer Cachexia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Cancer Cachexia, H1 2016
  • Number of Products under Development for Cancer Cachexia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top